Coadministration has not been studied. Dulaglutide is degraded by general protein catabolism pathways therefore no metabolic interaction is expected. Dulaglutide delays gastric emptying but interaction studies showed no clinically significant effect on the absorption of concomitantly orally administered drugs. No interaction is expected with dolutegravir. However, caution is needed when coadministering rilpivirine and GLP-1 agonists such as dulaglutide due to their potential to inhibit gastric secretion and thereby reduce the absorption of rilpivirine. Consider monitoring virological response after initiating dulaglutide.